



iJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 11 Issue: VIII Month of publication: Aug 2023

DOI: <https://doi.org/10.22214/ijraset.2023.55297>

www.ijraset.com

Call:  08813907089

E-mail ID: ijraset@gmail.com

Quantitative Analysis of Drug from Bulk as Well as Formulation

Omkar Deshmukh¹, Sonali Mehendre², Smita Nayak³

¹Department of Quality Assurance, ³Department of Pharmaceutics, Gahlot Institute of Pharmacy, Koparkhairane, NaviMumbai, 400 709, Maharashtra, India

²Shuban Pharmaceuticals Pvt. Ltd. I-115 Rajlaxmi Commercial Kalher, Bhiwandi –421302, Maharashtra, India

Abstract: A simple, precise, accurate method was developed for the estimation of molnupiravir by RP HPLC. Chromatographic conditions used are stationary phase Hemochrom C18 (4.6mm x 250mm x 5µm), mobile phase methanol for 5 minutes then 0.1% orthophosphoric acid and methanol in a ratio of 50:50 from 5 – 20 min. The flow rate was maintained at 1.0 ml/min, the detection wavelength was 235 nm, column temperature was set to 30 C and diluent were water and methanol (50:50) was finalized as an optimized method. System suitability parameters were studied by injecting the standard six times and the results were well under acceptance limits. Theretention time for molnupiravir was 10 min. The method was validated for linearity, accuracy, precision, specificity, the limit of quantification, detection, and robustness. The limit of detection and limit of quantification was found to be 0.5 µg/ml and 1.5 µg/ml respectively and recovery of molnupiravir from molnupiravir capsule was found 98.72 %. The proposed method was successfully applied for the quantitative determination of molnupiravir capsule formulation.

Keywords: Molnupiravir, RP-HPLC, Method Development, Validation, Forced Degradation, Peak purity index.

I. INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new coronavirus (CoV), which is the cause of the COVID-19 pandemic, has grown to be a significant concern to public health. More than 115 million individuals will have contracted the disease by March 8th, 2021, and sadly, approximately 2.5 million will have perished [1]. Molnupiravir, an antiviral medication with two brand names (MK-4482 and EIDD-2801) that is used to treat influenza, is one of the useful medications in this regard [2]. This prodrug, which is being developed by Merck firm as a novel oral anti-viral medication for the treatment of COVID-19, has a nucleoside scaffold of N4-hydroxycytidine [3],[4]. It was initially created at Emory University with the assistance of the university's drug discovery company. Molnupiravir efficacy in preventing viral transmission and inhibiting SARS-CoV 22 was shown by testing the medication on various animal species [5],[6],[7],[8],[9]. This medication, which is based on an oral antiviral ribonucleoside analog, is known as a 5'-isobutyrate prodrug of the direct-acting antiviral ribonucleoside analog EIDD-1931 or - D N4-hydroxy cytidine. EIDD-1931 is produced in the plasma when molnupiravir cleaves [10],[11]. The active anti-viral drug, EIDD-1931 5'-triphosphate, is phosphorylated intracellularly by host kinases. Molnupiravir IUPAC name is ((2R,3S,4R,5R)Its chemical name is C13H19N3O7, and its molecular formula is 4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)methyl isobutyrate. Molnupiravir has a 329.31 molecular weight [12]

A review of the literature found that molnupiravir pharmacokinetics studies were done in people. The effectiveness and safety of molnupiravir and numerous other drugs were also compared in controlled field research. Molnupiravir can be separated using a liquid chromatographic process that has been verified [13],[14],[15].




Fig.1 Chemical structure of Molnupiravir

Here, efforts were undertaken to establish a reverse phase chromatographic method (RP-HPLC) that was straightforward, precise, quick, accurate, and cost-effective for estimating molnupiravir in bulk and formulation. Additionally, techniques like uv-vis techniques are insufficient to calculate an exact amount of API. The study of this API similarly reveals insufficient resolution due to poor reproducibility [16],[17],[18]. Keeping this in mind the RP-HPLC method was developed and validated for quantification. Therefore, in the present investigation, a novel HPLC method was developed and validated for the quantification of this API and degradation studies under ICH guidelines [19].

II. MATERIAL AND METHODS

A. Instrumentation

HPLC instrument used was of Shimadzu iprominence with PDA detector. The software used is Lc lab solutions. UV – VIS spectrophotometer PG instrument T 60 with special bandwidth of 2nm and 10 nm and matched quartz was used for measuring absorbance for molnupiravir [20].

B. Chemicals

The molnupiravir reference standard was obtained from the capsule of the brand Moluzen (Xenon pharma) of 200mg was obtained from Shuban Pharmaceutical Pvt Ltd, Bhiwandi (India), and also molnupiravir standard was supplied by Shuban Pharmaceutical Pvt Ltd, Bhiwandi (India).

C. Chromatographic conditions

Glasswares in each procedure were soaked overnight in a hot air oven. Hemochrom C18 (4.6mm x 250mm x 5 μ m) was used at 30 \cdot C. Gradient elution was performed with 0-5 min (100% of 0.1% OPA), and 5-20 min (0.1% OPA: methanol in ratio of 50:50).

D. Preparation of standard solutions

Accurately weigh 50 mg std molnupiravir in a 50 ml volumetric flask and sonicated for 10 minutes. Flask was made up to the mark by water (stock sample solution). Take 1ml from stock , add in 100 ml flask. Add some amount of diluent (water and methanol in the ratio of 50:50). Sonicated it for 10 minutes. Flask was made up to the mark by diluent.

E. Preparation of sample solution

Ten capsules of (Moluzen, 200 mg) have been weighed and mixed with the powder. Accurately weighed tablet powder containing 60 mg of molnupiravir was transferred to a 50 ml calibrated flask and dissolved in deionized water. The content was shaken for 30 min. The volume was completed with deionized water to get the concentration of 1000 μ g mL⁻¹ (stock sample solution). Then further sample solution was made to get 10 μ g/mL solution by adding 1 ml from stock in a 100 ml flask and then diluting with diluent in the ratio of 50:50 (water: methanol). The final solution was filtered using a Whatman filter paper (No. 42) [21].

III. METHOD VALIDATION

The proposed method was validated as per ICH Q2 (R1) guidelines for specificity, linearity, range, accuracy, precision, and robustness.

A. Specificity

Specificity, also known as selectivity, is the ability of an analytical method to measure the analyte of interest accurately in the presence of potential interfering substances. It ensures that the method can distinguish and quantify the target analyte without being affected by other components in the sample matrix. To assess specificity forced Degradation Studies is carried out Subject the analyte to various stress conditions (e.g., heat, light, acid, base) to assess if the method can accurately detect and quantify degradation products.

B. Linearity

Linearity refers to the ability of the analytical method to produce results that are directly proportional to the concentration of the analyte in the sample over a specific range. A linear relationship implies that the method's response is consistent and predictable across a range of concentrations.

C. Range

In High-Performance Liquid Chromatography (HPLC) method validation, the term "range" refers to the concentration interval over which the analytical method is expected to provide accurate and precise results. Determining the appropriate range for your HPLC method is crucial for ensuring that the method can effectively quantify the analyte of interest within the desired concentration levels.

D. Accuracy

To assess the accuracy of the proposed method, recovery studies were carried out at three different levels i.e. 50 %, 75%, 100%, and 150%. To the pre-analyzed sample solution, a known amount of standard drug solution was added at three different levels, absorbance was recorded. The % recovery was calculated by using the formula

$$\% \text{ recovery} = \frac{A - B}{C}$$

Where A = total amount of drug estimated, B= amount of drug found on pre analyzed basis, C= amount of pure drug added

E. Precision

Precision assessment in HPLC method validation provides insights into the method's ability to generate consistent and reliable results, which is crucial for obtaining accurate data in analytical work. It helps ensure that the method is suitable for its intended purpose and that the variability in results is within acceptable limits.

F. Robustness

Small deliberate changes in a method like flow rate, mobile phase ratio, and temperature are made but there were no recognized changes in the result, and are within the range as per ICH guidelines [22],[23],[24].

IV. RESULTS

A. Selection of detection wavelength

The UV spectra of molnupiravir in methanol in the region between 200 to 400 nm are shown in Fig 2. It shows that at 235 nm molnupiravir has maximum absorbance. Hence max of molnupiravir in the mobile phase was selected as the optimum detection wavelength for quantification of molnupiravir




Fig. 2 Absorbance spectrum of molnupiravir in methanol

B. Optimized chromatographic conditions

- 1) Column: Hemochrom C18 (4.6mm x 250mm x 5µm)
- 2) Mobile phase: 0-5 min (100% of 0.1 % OPA), 5-20 min (OPA and methanol in ratio of 50:50)(iii)
- 3) Flow rate: 1.0ml/min
- 4) Detector: PDA detector
- 5) Temperature: 30° C
- 6) Injection volume: 10µL [25]

C. Robustness, limit of detection, and limit of quantification

Robustness was done by changing parameters like mobile phase ratio, and flow rate. LOD and LOQ are calculated by the S/N ratio.

D. System suitability

The Standard solution of molnupiravir working standard was prepared as per procedure and was injected 5 times into the HPLC system. The system suitability parameters were evaluated from a standard chromatogram obtained by calculating % RSD of retention time, tailing factor, theoretical plates, and peak areas from the above replicate injection are within range and results were shown in Table 1.




Fig. 3 Optimized chromatographic conditions

Table. 1 System suitability data

Sr.no	Peak name	Area	Retention time	USP plate count	USP tailing
1	Molnupiravir	235033	10.0	25544	0.97
2	Molnupiravir	235335	10.0	25458	0.97
3	Molnupiravir	236130	9.9	25802	0.98
4	Molnupiravir	235469	10.0	26020	0.99
5	Molnupiravir	235975	10.0	26159	0.99
6	Molnupiravir	236129	10.0	25562	0.97
	Mean	235678.5	10.0		
	SD	463.3071	0.017		
	%RSD	0.196	0.167		
	Limit	NMT 2.0%	MMT 1.0 %		

E. Linearity

The method can elicit test result that is directly proportional to analyte concentration within a given range. It is generally reported as the variance of the slope or regression line. The appropriate volume of standard stock solution was transferred to a volumetric flask of 100 ml capacity. The volume was adjusted to the mark with diluent to give a solution containing 10, 20, 40, 80, 100, 200 ppm. The slope, Y-intercept, and correlation coefficient were calculated. The regression line relating to the standard concentration of the drug using regression analysis was calculated. The calibration curve was linear in the standard range and an equation of regression analysis was obtained.

Table. 2 Linearity data of molnupiravir

Concentration (µg/ml)	InjectionNo	Area	Average
10	1	225269	225126
	2	224983	
20	1	473717	464075
	2	464433	
40	1	918736	918761
	2	918786	
80	1	1918970	1918750
	2	1918530	
100	1	2369877	2368810
	2	2367742	
200	1	2732495	2732328
	2	2732161	




Fig. 4 Calibration curve of molnupiravir

F. Range

The linearity of an analytical procedure is its ability (within a given range) to obtain test results that are directly proportional to the concentration (amount) of analyte in the sample. The conc. The range is between 10 to 200 µg/ml.

G. LOD and LOQ

LOD and LOQ were calculated from the formula $3.3 \times (\sigma/S)$ and $10 \times (\sigma/S)$ respectively where σ is the standard deviation of intercept and S is the mean of slope. The LOD and LOQ can be determined by S/N.

The value for LOD should be 0.5 $\mu\text{g/ml}$ and 1.5 $\mu\text{g/ml}$.

H. Precision

1) System precision: Six working standard solutions of 10 ppm are injected and % amount found was calculated and the % RSD was found to be 0.196

Table. 3 System precision

Injection No.	Area	Limit
1	235033	NMT 2.0%
2	235335	
3	236130	
4	235469	
5	235975	
6	236129	
Mean	235678.5	
SD	463.3071	
%RSD	0.196	
Limit	NMT 2.0%	

2) Method precision: Six working standards and a sample of 10 ppm were injected into the HPLC system and the % amount found was calculated and the % RSD was found to be 0.312.

Table. 4 Method precision

Sample no	% Assay	Limit
1	98.57	NMT 2.0 %
2	99.32	
3	98.98	
4	98.97	
5	99.41	
6	98.85	
mean	99.01	
SD	0.3090	
% RSD	0.312	

3) Interday Precision: Six working standards and a sample of 10 ppm were injected on the next day of preparation of samples and the % amount found was calculated and the % RSD was found to be within specified limits of acceptance criteria: the % RSD for all six standard injections should be not more than 2.0%.

Table. 5 Interday precision

Sample No	Day 1	Day 2	Limit
1	98.57	99.01	NMT 2.0 %
2	99.32	99.64	
3	98.98	98.96	
4	98.97	99.23	
5	99.41	99.46	
6	98.85	99.83	
Mean	99.01	99.35	
SD	0.3090	0.3488	
% RSD	0.312	0.251	

I. Accuracy

Four concentrations of 50%, 75%, 100%, and 150% were injected and % recovery was calculated as 98.72%.

Table. 6 Accuracy and recovery

% level	Amount added (µg/ml)	Amount recovered(mg)	% amount recovered	% recovered	Mean % recovered
50	25	24.6	49.24	98.13	98.72%
75	37.5	37.4	74.78	99.71	
100	50	49.4	98.89	98.89	
150	75	73.7	147.25	98.17	

J. Assay of marketed formulation

Standard and sample solutions were injected after a 0.45 µm syringe filter into the system and the drug present in samples was calculated using formula [26],[27],[28].

Table. 7 Assay of molnupiravir

SampleNo	Weight of standard(mg)	Sample weight (equivalent to 50mg)	The mean area of the standard at 235 nm	Area of the sample at 235nm	% Assay
1	50 mg		235619	230106	98.57
2				231863	99.32
3				231079	98.98
4				231060	98.97
5				232087	99.41
6				230771	98.85
			Mean	231161	99.01
Average Weight	50.5 mg	60.1 mg	SD	725.57	0.309
Limit	NMT 2.0%		% RSD	0.313	0.312




Fig. 5 Assay chromatogram of molnupiravir

V. FORCED DEGRADATION STUDIES

Degradation studies were performed with formulation and degraded samples were injected. The assay of injected samples was calculated and all the samples were passed the limit of degradation. Degradation sample preparation are as given below.

A. Acid degradation studies

To the 1ml of stock sample solution, 1ml of 0.1 N HCL was added separately in a 100 ml flask. The solution was kept at 60° C for 4 hrs. for the HPLC study, the resultant solution was diluted with diluent to obtain 10 µg/ml, and 10 µl was injected into the system after filtering through a syringe filter, and a chromatogram was recorded to assess the stability of the sample.

B. Alkali degradation studies

To the 1ml of stock sample solution, 1ml of 0.01 N NaOH was added separately in a 100 ml flask. The solution was kept at room temperature for 2 mins. For the HPLC study, the resultant solution was diluted with diluent to obtain 10 µg/ml, and 10 µl was injected into the system after filtering through a syringe filter, and chromatograms were recorded to assess the stability of the sample.

C. Oxidative degradation studies

To the 1ml of stock sample solution, 1ml of 5 % H₂O₂ was added separately in a 100 ml flask. The solution was kept at 60° C for 4 hrs. For the HPLC study, the resultant solution was diluted with diluent to obtain 10 µg/ml, and 10 µl was injected into the system after filtering through a syringe filter, and a chromatogram was recorded to assess the stability of the sample.

D. Water degradation studies

To the 1ml of stock sample solution, 1ml of water was added separately in a 100 ml flask. The solution was kept at 60° C for 4 hrs. For the HPLC study, the resultant solution was diluted with diluent to obtain 10 µg/ml, and 10 µl was injected into the system after filtering through a syringe filter, and a chromatogram was recorded to assess the stability of the sample [29].

Table. 8 Degradation data of molnupiravir

Sr no	Degradation type	Conditions	Duration	Retention time on degradation products (min)	% residual Drug(%)	Observed peak purity	Acceptance limit of peak purity
1	Acid degradation	1ml of 0.1NHCL at 60° C	4 hrs	10.2	94.21	100.00	NLT 99 %
2	Alkaline degradation	1ml of 0.01N NaOH at room temperature	2 min	10.3	96.94	100.00	
3	H ₂ O ₂ degradation	1 ml of 5% H ₂ O ₂ at 60° C	4 hrs	10.2	97.63	100.00	
4	Water degradation	1ml of H ₂ O at 60° C	4 hrs	10.2	100.00	100.00	




Fig. 6 Blank chromatogram




Fig. 7 Chromatogram of acid degradation




Fig. 7A Peak purity index in acidic degradation




Fig. 8 Chromatogram of alkaline degradation




Fig. 8A Peak purity index in alkaline degradation




Fig 9 Chromatogram of hydrogen peroxide degradation




Fig. 9 A. Peak purity index hydrogen peroxide degradation




Fig. 10 Chromatogram of hydrolytic degradation




Fig 10A. Peak purity index in hydrolytic degradation

VI. DISCUSSION

Regarding the p^H adjustment in the mobile phase for acid and base degradation studies have movement in the retention time of the drugs. But due to the addition of OPA, there will be no change in retention time. The summarized data is shown in Table 9.

Table 9. Summarized data

Parameters	Molnupiravir	Limit
Linearity: Range ($\mu\text{g/ml}$)	10 – 200 $\mu\text{g/ml}$	R < 1
Regression coefficient	0.9998	
Slope (m)	1376.5	
Intercept (c)	218.15	
Regression equation($y=mx+c$)	$Y= 1376.5 x +218.15$	
Assay (% mean assay)	99.01 %	98 – 102 %
Specificity	Specific	No interference of anypeak
System precision % RSD	0.196	NMT 2.0 %
Method precision % RSD	0.312	
Interday precision % RSD	0.251	
Accuracy & recovery %	98.72 %	98 – 102 &
LOD	0.5 ($\mu\text{g/ml}$)	NMT 3
LOQ	1.5 ($\mu\text{g/ml}$)	NMT 10
Robustness Wavelength ($\pm 2 \text{ nm}$)	0.689	% RSD NMT 2.0 %
Mobile Phase ($\pm 2\text{ml}$)	0.292	
Flow rate ($\pm 0.2\text{ml/min}$)	0.585	

VII. CONCLUSION

Chromatographic conditions used are stationary phase Hemochrom C18 (4.6mm x 250mm x 5 μ m), mobile phase for 0-5 min 100% orthophosphoric acid, for 5- 20 min 0.1% orthophosphoric acid and methanol in ratio of 50:50 and flow rate were maintained at 1.0 ml/min, detection wavelength was 235 nm, column temperature was set to 30 $^{\circ}$ C and diluent methanol and water in a ratio of 50:50 were finalized as an optimized method. Systemsuitability parameters were studied by injecting the standard six times and the results were all under the acceptancecriteria. A linearity studywas carried out between 10–200, R² value was found to be 0.9998. precision was foundto be 0.312 for the method and 251 for interday precision. LOD and LOQ were found to be 0.5 and 1.5 respectively. By using the above method assay of the marketed formulation was carried out. Degradation studies of molnupiravir were done, in all conditions purity threshold was more than the purity angle and within the acceptable range.

VIII. ACKNOWLEDGMENT

The author is thankful to the Director of Gelnova Lab Pvt Ltd, Turbhe and Gahlot Institute of Pharmacy, Koparkhairane to provide the necessary facilities to carry out our research work and constant support to our entire research work. Special thanks to Dr. Ratnakar Mehendre, Dr. Sonali Mehendre, Dr. Smita Nayak, and Dr. V.H. Bhaskar for valuable guidance and support.

REFERENCES

- [1] Grubaugh, N. D., Hodcroft, E. B., Fauver, J. R., Phelan, A. L., & Cevik, M. (2021). Public health actions to control new SARS-COV-2 variants. *Cell*, 184(5), 1127–1132.
- [2] Toots, M., Yoon, J.-J., Cox, R. M., Hart, M., Sticher, Z. M., Makhsous, N., ... Plemper, R. K. (2019). Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. *Science Translational Medicine*, 11(515).
- [3] Toots, M., Yoon, J.-J., Hart, M., Natchus, M. G., Painter, G. R., & Plemper, R. K. (2020). Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. *Translational Research*, 218, 16–28. doi:10.1016/j.trsl.2019.12.002
- [4] Ryan Cross. (2020a). Merck & Co. joins race for covid-19 vaccines and therapies. *C&EN Global Enterprise*, 98(21), 12–12.
- [5] Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., ... Baric, R. S. (2020). An orally bioavailable broad-spectrum antiviral inhibits SARS-COV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Science Translational Medicine*, 12(541).
- [6] Hernandez-Santiago, B. I., Beltran, T., Stuyver, L., Chu, C. K., & Schinazi, R. F. (2004). Metabolism of the anti-hepatitis C virus nucleoside β - hydroxycytidine in different liver cells. *Antimicrobial Agents and Chemotherapy*, 48(12), 4636–4642.
- [7] Painter, G. R., Bowen, R. A., Bluemling, G. R., DeBergh, J., Edpuganti, V., Gruddanti, P. R., ... Kolykhalov, A. A. (2019). The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection. *Antiviral Research*, 171, 104597.
- [8] National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 145996610, Molnupiravir. Retrieved August 11, 2023 from <https://pubchem.ncbi.nlm.nih.gov/compound/Molnupiravir>.
- [9] Zarenezhad, E., & Marzi, M. (2022). Review on molnupiravir as a promising oral drug for the treatment of covid-19. *Medicinal Chemistry Research*, 31(2), 232–243.
- [10] Yuwono, M., & Indrayanto, G. (2005). Validation of chromatographic methods of analysis. *Profiles of Drug Substances, Excipients and Related Methodology*, 243–259.
- [11] Pourkarim, F., Pourtaghi-Anvarian, S., & Rezaee, H. (2022). Molnupiravir: A new candidate for COVID-19 treatment. *Pharmacology research & perspectives*, 10(1), e00909.
- [12] National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 145996610, EIDD-2801. Retrieved March 24, 2023, from <https://pubchem.ncbi.nlm.nih.gov/compound/eidd-2801>.
- [13] Abdelnabi, R., Foo, C. S., De Jonghe, S., Maes, P., Weynand, B., & Neyts, J. (2021). Molnupiravir inhibits replication of the emerging SARS-COV-2 variants of concern in a hamster infection model. *The Journal of Infectious Diseases*, 224(5), 749–753.
- [14] Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F., & Götte, M. (2021). Molnupiravir promotes SARS-COV-2 mutagenesis via the RNA template. *Journal of Biological Chemistry*, 297(1), 100770. 100770
- [15] Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, Vangeel L, Breuer J, Pang J, Williams R, Vergote V, Heylen E, Leyssen P, Dallmeier K, Coelmont L, Chatterjee AK, Mols R, Augustijns P, De Jonghe S, Jochmans D, Weynand B, Neyts J. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. *EBioMedicine*. 2021 Oct;72:103595.
- [16] Imran, Mohd., Kumar Arora, M., Asdaq, S. M., Khan, S. A., Alaqel, S. I., Alshammari, M. K., ... Abida, A. (2021). Discovery, development, and patent trends on molnupiravir: A prospective oral treatment for covid-19. *Molecules*, 26(19), 5795.
- [17] Painter, G. R., Natchus, M. G., Cohen, O., Holman, W., & Painter, W. P. (2021). Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for covid-19. *Current Opinion in Virology*, 50, 17–22.
- [18] Malviya R, Bansal V, Pal O P, Sharma P K. High-performance liquid chromatography: a short review. *Journal of Global Pharma Technology*. 2010; 2(5): 22- 26.
- [19] Guideline, I. H. T. (2005). Validation of analytical procedures: text and methodology. Q2 (R1), 1(20), 05.
- [20] Annadi, A. M., El Zahar, N. M., El-Din A. Abdel-Sattar, N., Mohamed, E. H., Mahmoud, S. A., & Attia, M. S. (2022). Development and validation of molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method. *RSC Advances*, 12(53), 34512–34519.



- [21] Reçber, T., Timur, S. S., Erdoğan Kablan, S., Yalçın, F., Karabulut, T. C., Neslihan Gürsoy, R., ... Nemutlu, E. (2022). A stability indicating rp-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. *Journal of Pharmaceutical and Biomedical Analysis*, 214, 114693.
- [22] Mangukiya, M. A., Bagwe, P. V., Desai, A., & Joshi, S. V. (2022). DEVELOPMENT AND VALIDATION OF A NOVEL STABILITY INDICATING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR RELATED SUBSTANCES AND ASSAY ANALYSIS OF MOLNUPIRAVIR DRUG SUBSTANCE AND DRUG PRODUCT. *Indian Drugs*, 59(12).
- [23] Sharaf, Y. A., El Deeb, S., Ibrahim, A. E., Al-Harrasi, A., & Sayed, R. A. (2022). Two green micellar HPLC and mathematically assisted UV spectroscopic methods for the simultaneous determination of Molnupiravir and favipiravir as a novel combined covid-19 antiviral regimen. *Molecules*, 27(7), 2330.
- [24] Saraya, R. E., Deeb, S. E., Salman, B. I., & Ibrahim, A. E. (2022). Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations. *Journal of Separation Science*, 45(14), 2582–2590.
- [25] Bindu M, Gandla K, Vemireddy S, Samuel S, Praharsha Y. A validated stability indicating RP-HPLC method for the determination of molnupiravir in a pharmaceutical dosage form. *World Journal of Advanced Research and Reviews*. 2022;15(01):580–590.
- [26] Camlik, G., Beyazaslan, F., Kara, E., Ulker, D., Albayrak, I., & Degim, I. T. (2022). A Validated High-Pressure Liquid Chromatography (HPLC) Method for Molnupiravir. *Medical Research Archives*, 10(9).
- [27] Suresh, C. V., Mamatha, T., & Santhosh Illendula, D. K. AN ANALYTICAL NEW RP-HPLC METHOD FOR THE QUANTITATIVE DETERMINATION OF MOLNUPIRAVIR IN BULK AND TABLET DOSAGE FORM.
- [28] Sravanthi, G., Gandla, K., & Repudi, L. (2023). New Analytical Method Development and validation for estimation of molnupiravir in bulk and tablet dosage form by RP-HPLC method. *Cellular, Molecular and Biomedical Reports*, 3(3), 130–136. doi:10.55705/cmbr.2023.375093.1087
- [29] Kumar, G. R., Babu, B. S., Rao, R. R., Vardhan, V. M., & Abbaraju, V. D. (2021). Method development and validation of a specific stability indicating RP-HPLC method for Molnupiravir API. *Journal of Pharmaceutical Research International*, 3026–3035.



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)